Page last updated: 2024-09-05

sb 203580 and lentinan

sb 203580 has been researched along with lentinan in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (lentinan)	Trials (lentinan)	Recent Studies (post-2010) (lentinan)
3,489	4	1,137	495	36	152

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dai, S; Dong, L; Li, H; Liu, Q; Peng, Y; Yuan, J	1

Other Studies

1 other study(ies) available for sb 203580 and lentinan

Article	Year
Lentinan mitigates therarubicin-induced myelosuppression by activating bone marrow-derived macrophages in an MAPK/NF-κB-dependent manner. Oncology reports, 2016, Volume: 36, Issue:1 Topics: Animals; Anthracenes; Bone Marrow; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; I-kappa B Proteins; Imidazoles; Lentinan; Leukocytes; Macrophages; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neutrophils; NF-kappa B; Pyridines	2016

Article

Year

Lentinan mitigates therarubicin-induced myelosuppression by activating bone marrow-derived macrophages in an MAPK/NF-κB-dependent manner.

Oncology reports, 2016, Volume: 36, Issue:1

Topics: Animals; Anthracenes; Bone Marrow; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; I-kappa B Proteins; Imidazoles; Lentinan; Leukocytes; Macrophages; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neutrophils; NF-kappa B; Pyridines

2016